tazobactam has been researched along with amoxicillin-potassium clavulanate combination in 9 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (amoxicillin-potassium clavulanate combination) | Trials (amoxicillin-potassium clavulanate combination) | Recent Studies (post-2010) (amoxicillin-potassium clavulanate combination) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 2,827 | 612 | 1,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Baquero, F; Martínez, JL; Pérez-Díaz, JC; Reguera, JA | 1 |
| Livermore, DM; Seetulsingh, P | 1 |
| Cherubin, CE; Eng, RH; Smith, SM | 1 |
| Blahová, J; Hupková, M; Krcméry, V | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Baquero, F; Cantón, R; Galán, JC; Novais, A; Ripoll, A; Rodríguez-Domínguez, MJ; Turrientes, MC | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Freemantle, N; Nisar, S; Ray, D; Shallcross, LJ | 1 |
| Adams, R; Agus, A; Barnes, RA; Chau, I; Clarke, M; Coyle, V; Doran, A; Forde, C; Grayson, M; McAuley, DF; McDowell, C; McMullan, R; Plummer, R; Thomas, AL; Wilson, RH | 1 |
3 trial(s) available for tazobactam and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Drug Administration Schedule; Equivalence Trials as Topic; Humans; Meropenem; Multicenter Studies as Topic; Neoplasms; Neutropenia; Piperacillin; Pragmatic Clinical Trials as Topic; Quality of Life; Sepsis; Tazobactam; Treatment Outcome | 2020 |
6 other study(ies) available for tazobactam and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Cell Membrane Permeability; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
Beta-lactamase inhibitors and Acinetobacter spp.
Topics: Acinetobacter; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Species Specificity; Sulbactam; Tazobactam | 1990 |
[The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Bacteria; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1995 |
In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Clavulanic Acid; DNA, Bacterial; Escherichia coli; Escherichia coli Proteins; Evolution, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Plasmids; Selection, Genetic; Tazobactam | 2011 |
A cross-sectional study of blood cultures and antibiotic use in patients admitted from the Emergency Department: missed opportunities for antimicrobial stewardship.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Bacteremia; Cross-Sectional Studies; Emergency Service, Hospital; Female; Hospitals, University; Humans; Male; Microbiological Techniques; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2016 |